Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: Results from ECOG Trial E4402 (RESORT)

Journal of Clinical Oncology

Volumn 33, Issue 7, 2015, Pages 740-748

  Wagner, Lynne I ^a   Zhao, Fengmin ^b   Hong, Fangxin ^b   Williams, Michael E ^c   Gascoyne, Randy D ^m   Krauss, John C ^d   Advani, Ranjana H ^e   Go, Ronald S ^g   Habermann, Thomas M ⁱ   Leach, Joseph W ^j   O'Connor, Brian ^k   Schuster, Stephen J ^l   Cella, David ^a   Horning, Sandra J ^f   Kahl, Brad S ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e STANFORD UNIVERSITY   (United States)

^f GENENTECH INC   (United States)

^g Gunderson Health System   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁱ MAYO CLINIC   (United States)

^j Metro Minnesota Community Clinical Oncology Program   (United States)

^k MEMORIAL HEALTH SYSTEM   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CHILD; COPING BEHAVIOR; DISEASES; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IMPACT OF EVENTS SCALE; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT WORRY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STUDENT T TEST; TUMOR VOLUME; WELLBEING; ADAPTIVE BEHAVIOR; ADULT; AGED; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEALTH STATUS; HEALTH SURVEY; LYMPHOMA, NON-HODGKIN; MENTAL STRESS; MIDDLE AGED; PATHOLOGY; PSYCHOLOGY;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANXIETY; DEPRESSION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; QUALITY OF LIFE; RITUXIMAB; STRESS, PSYCHOLOGICAL; TUMOR BURDEN;

EID: 84925238573     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.6801     Document Type: Article

References (43)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. Cancer 64:9-29, 2014
2. Voliotis D, Diehl V: Challenges in treating hematologic malignancies. Semin Oncol 29:30-39, 2002
3. Foster T, Miller JD, Boye ME, et al: Economic burden of follicular non-Hodgkin's lymphoma. Pharmacoeconomics 27:657-679, 2009
4. Smith SK, Zimmerman S, Williams CS, et al: Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 115:3312-3323, 2009
5. Smith SK, Mayer DK, Zimmerman S, et al: Quality of life among long-term survivors of non- Hodgkin lymphoma: A follow-up study. J Clin Oncol 31:272-279, 2013
6. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607-1614, 2009
7. Oerlemans S, Mols F, Issa DE, et al: A high level of fatigue among long-term survivors of non- Hodgkin's lymphoma: Results from the longitudinal population-based PROFILES registry in the south of the Netherlands. Haematologica 98:479-486, 2013
8. Jensen RE, Arora NK, Bellizzi KM, et al: Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. Cancer 119: 672-680, 2013
9. Smith SK, Crespi CM, Petersen L, et al: The impact of cancer and quality of life for posttreatment non-Hodgkin lymphoma survivors. Psychooncology 19:1259-1267, 2010
10. Pettengell R, Donatti C, Hoskin P, et al: The impact of follicular lymphoma on health-related quality of life. Ann Oncol 19:570-576, 2008
11. Allart P, Soubeyran P, Cousson-Gélie F: Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature. Psychooncology 22:241-249, 2013
12. Smith SK, Zimmerman S, Williams CS, et al: Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors. J Clin Oncol 26:934-941, 2008
13. Montgomery C, Pocock M, Titley K, et al: Individual quality of life in patients with leukaemia and lymphoma. Psychooncology 11:239-243, 2002
14. Montgomery C, Pocock M, Titley K, et al: Predicting psychological distress in patients with leukaemia and lymphoma. J Psychosom Res 54: 289-292, 2003
15. Witzens-Harig M, Reiz M, Heiss C, et al: Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: Results of a prospective randomized controlled trial. Ann Hematol 88:51-57, 2009
16. Ardeshna KM, Qian W, Smith P, et al: Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 15:424-435, 2014
17. Kahl BS, Hong F, Williams ME, et al: Rituximab Extended Schedule or Retreatment Trial (RESORT) for low tumor burden follicular lymphoma: Eastern Cooperative Oncology Group Protocol E4402. J Clin Oncol 32:3096-3102, 2014
18. Calvert M, Blazeby J, Altman DG, et al: Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA 309: 814-822, 2013
19. Williams ME, Hong F, Kahl BS, et al: A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. J Clin Oncol 30, 2012 (suppl; abstr 8007)
20. Weiss D, Marmar C: The Impact of Events Scale-Revised, in Wilson J, Keane T (eds): Assessing Psychological Trauma and PTSD (ed 2). New York, NY, Guilford Press, 2004, pp 168-189
21. Horowitz M, Wilner N, Alvarez W: Impact of Event Scale: A measure of subjective stress. Psychosom Med 41:209-218, 1979
22. Folkman S, Lazarus RS: The relationship between coping and emotion: Implications for theory and research. Soc Sci Med 26:309-317, 1988
23. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
24. Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361-370, 1983
25. Moorey S, Greer S, Watson M, et al: The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer. Br J Psychiatry 158:255-259, 1991
26. Hlubocky FJ, Webster K, Cashy J, et al: The development and validation of a measure of health-related quality of life for non-Hodgkin's lymphoma: The Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym). Lymphoma 2013: 1-9, 2013
27. Lai JS, Garcia SF, Salsman JM, et al: The psychosocial impact of cancer: Evidence in support of independent general positive and negative components. Qual Life Res 21:195-207, 2012
28. Watson M, Law M, dos Santos M, et al: The Mini-MAC: Further development of the mental adjustment to cancer scale. J Psychosoc Oncol 12:33-46, 1994
29. Osborne RH, Elsworth GR, Kissane DW, et al: The Mental Adjustment to Cancer (MAC) scale: Replication and refinement in 632 breast cancer patients. Psychol Med 29:1335-1345, 1999
30. Cella D: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT Scales). Version 4. Elmhurst, IL, FACIT.org, 1997
31. Webster K, Cashy J, Cella D, et al: Measuring quality of life (QOL) among patients with non- Hodgkin's lymphoma (NHL): The Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM). Qual Life Res 14:2103, 2005
32. Yost KJ, Thompson CA, Eton DT, et al: The Functional Assessment of Cancer Therapy-General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma 54:290-297, 2013
33. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases eventfree survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004
34. Yost KJ, Eton DT: Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Eval Health Prof 28:172-191, 2005
35. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3,randomised controlled trial. Lancet 377:42-51, 2011
36. Stanton AL: Psychosocial concerns and interventions for cancer survivors. J Clin Oncol 24:5132-5137, 2006
37. Jacobsen PB, Jim HS: Psychosocial interventions for anxiety and depression in adult cancer patients: Achievements and challenges. CA Cancer J Clin 58:214-230, 2008
38. Antoni MH, Wimberly SR, Lechner SC, et al: Reduction of cancer-specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer. Am J Psychiatry 163:1791-1797, 2006
39. Traeger L, Greer JA, Fernandez-Robles C, et al: Evidence-based treatment of anxiety in patients with cancer. J Clin Oncol 30:1197-1205, 2012
40. Leykin Y, Thekdi SM, Shumay DM, et al: Internet interventions for improving psychological well-being in psycho-oncology: Review and recommendations. Psychooncology 21:1016-1025, 2012
41. Schnipper LE, Smith TJ, Raghavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715-1724, 2012
42. Schnipper LE, Lyman GH, Blayney DW, et al: American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol 31:4362-4370, 2013
43. Kahl B: Is there a role for "watch and wait" in follicular lymphoma in the rituximab era? ASH Education Program Book 2012:433-438, 2012